LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the ALK-Positive Lung Cancer Research Award Program. This year, the patient oncogene group will potentially fund research projects totaling up to $1.5 million over two years—their largest funding to date. The ultimate goal of the research is to transform ALK-positive lung cancer into a chronic or curable condition.
“ALK Positive is delighted to partner once more with LUNGevity. Our partnership with LUNGevity leverages their rigorous selection process and access to experts to help us choose and support the research most likely to save the lives of patients and improve their quality of life,” notes Dr. Colin Barton, ALK-positive patient/survivor since 2016 and chair of ALK Positive’s Medical Committee. “This $1.5 million research award program is our biggest to date. The members and supporters of ALK Positive have made amazing efforts to raise the funds for this award program. Currently, there is no known cure for this type of cancer in its advanced stage.”
Research to be funded is expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission. Individual awards up to $750,000 over two years will be funded.
“We are excited to solicit another round of high-quality research proposals that will help to expand treatment options for patients with ALK-positive lung cancer,” says Upal Basu Roy, PhD, MPH, LUNGevity’s executive director of research. “Members of the ALK Positive group not only have fundraised for this program but will also be integral in the selection of these research projects. Awardees from the 2018 and 2020 programs have already made significant progress.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
